EP1631235A4 - Compositions et methodes de modulation de l'expression de la proteine b7 - Google Patents
Compositions et methodes de modulation de l'expression de la proteine b7Info
- Publication number
- EP1631235A4 EP1631235A4 EP04752823A EP04752823A EP1631235A4 EP 1631235 A4 EP1631235 A4 EP 1631235A4 EP 04752823 A EP04752823 A EP 04752823A EP 04752823 A EP04752823 A EP 04752823A EP 1631235 A4 EP1631235 A4 EP 1631235A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- modulation
- protein
- expression
- compositions
- methods
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/444,206 US20040023917A1 (en) | 1996-12-31 | 2003-05-23 | Oligonucleotide compositions and methods for the modulation of the expression of B7 protein |
US51061403P | 2003-10-10 | 2003-10-10 | |
US52040103P | 2003-11-13 | 2003-11-13 | |
US53729104P | 2004-01-16 | 2004-01-16 | |
PCT/US2004/015880 WO2005000202A2 (fr) | 2003-05-23 | 2004-05-19 | Compositions et methodes de modulation de l'expression de la proteine b7 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1631235A2 EP1631235A2 (fr) | 2006-03-08 |
EP1631235A4 true EP1631235A4 (fr) | 2008-05-21 |
Family
ID=33556628
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP04752823A Withdrawn EP1631235A4 (fr) | 2003-05-23 | 2004-05-19 | Compositions et methodes de modulation de l'expression de la proteine b7 |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP1631235A4 (fr) |
WO (1) | WO2005000202A2 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2553104A1 (fr) * | 2004-01-23 | 2005-08-11 | Avi Biopharma, Inc. | Oligomeres antisens et methodes destinees a induire la tolerance immunitaire et l'immunosuppression |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000074687A1 (fr) * | 1999-06-04 | 2000-12-14 | Isis Pharmaceuticals, Inc. | Modulation antisens de l'expression de la proteine b7 |
WO2003083089A2 (fr) * | 2002-03-28 | 2003-10-09 | Revivicor Inc. | Cellules tolerogenes presentant des antigenes |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2294988C (fr) * | 1997-07-01 | 2015-11-24 | Isis Pharmaceuticals Inc. | Compositions et procedes d'apport d'oligonucleotides par le tube digestif |
-
2004
- 2004-05-19 WO PCT/US2004/015880 patent/WO2005000202A2/fr active Application Filing
- 2004-05-19 EP EP04752823A patent/EP1631235A4/fr not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6319906B1 (en) * | 1996-12-31 | 2001-11-20 | Isis Pharmaceuticals | Oligonucleotide compositions and methods for the modulation of the expression of B7 protein |
WO2000074687A1 (fr) * | 1999-06-04 | 2000-12-14 | Isis Pharmaceuticals, Inc. | Modulation antisens de l'expression de la proteine b7 |
WO2003083089A2 (fr) * | 2002-03-28 | 2003-10-09 | Revivicor Inc. | Cellules tolerogenes presentant des antigenes |
Non-Patent Citations (6)
Title |
---|
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; February 2001 (2001-02-01), QIAN S ET AL: "Administration of antisense oligodeoxyribonucleotides against mRNA of CD80 or CD86 prolongs survival of cardiac allografts by inhibition of CTL activity", Database accession no. PREV200100372589 * |
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 27 August 2003 (2003-08-27), LIANG XIAOYAN ET AL: "Administration of dendritic cells transduced with antisense oligodeoxyribonucleotides targeting CD80 or CD86 prolongs allograft survival.", Database accession no. NLM12973117 * |
LIANG X ET AL: "PHENOTYPE AND ALLOSTIMULATORY FUNCTION OF DENDRITIC CELLS TREATED WITH ANTISENSE OLIGODEOXYRIBONUCLEOTIDES TARGETING CD80 OR CD86 MRNA", TRANSPLANTATION PROCEEDINGS, ORLANDO, FL, US, vol. 33, no. 1/02, 1 February 2001 (2001-02-01), pages 235, XP001036750, ISSN: 0041-1345 * |
LIANG X ET AL: "Phenotype and allostimulatory function of dendritic cells treated with antisense oligodeoxyribonucleotides targeting CD80 or CD86 mRNA.", TRANSPLANTATION PROCEEDINGS 2001 FEB-MAR, vol. 33, no. 1-2, February 2001 (2001-02-01), pages 235, XP001036750, ISSN: 0041-1345 * |
LIANG XIAOYAN ET AL: "Administration of dendritic cells transduced with antisense oligodeoxyribonucleotides targeting CD80 or CD86 prolongs allograft survival.", TRANSPLANTATION 27 AUG 2003, vol. 76, no. 4, 27 August 2003 (2003-08-27), pages 721 - 729, XP002474974, ISSN: 0041-1337 * |
QIAN S ET AL: "Administration of antisense oligodeoxyribonucleotides against mRNA of CD80 or CD86 prolongs survival of cardiac allografts by inhibition of CTL activity.", TRANSPLANTATION PROCEEDINGS 2001 FEB-MAR, vol. 33, no. 1-2, February 2001 (2001-02-01), pages 551, XP002474973, ISSN: 0041-1345 * |
Also Published As
Publication number | Publication date |
---|---|
EP1631235A2 (fr) | 2006-03-08 |
WO2005000202A2 (fr) | 2005-01-06 |
WO2005000202A3 (fr) | 2006-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1677735A4 (fr) | Methodes et compositions pour moduler la fonction des adipocytes | |
IL173440A0 (en) | Novel formulation of ropinirole | |
IL220263A0 (en) | Modulation of eif4e expression | |
AU2003295801A1 (en) | MODULATION OF HIF1Alpha AND HIF2Alpha EXPRESSION | |
AU2003259735A1 (en) | Small-mer compositions and methods of use | |
IL172689A0 (en) | Pro104 ANTIBODY COMPOSITIONS AND METHODS OF USE | |
GB0411940D0 (en) | Methods and compositions | |
EP1701725A4 (fr) | Methodes et compositions | |
AU2003267644A1 (en) | Dental compositions and methods | |
IL175509A0 (en) | Methods and agents for immune modulation | |
AU2003256805A1 (en) | Compounds compositions and methods | |
AU2003299441A1 (en) | Nf-hev compositions and methods of use | |
AU2003252072A8 (en) | Modulation of protein kinase c-iota expression | |
GB2384705B (en) | Cosmetic and related compositions | |
AU2003276844A8 (en) | Formulations of modified antibodies and methods of making the same | |
AU2003216354A8 (en) | Modulators of paraptosis and related methods | |
AU2003295790A8 (en) | Modulation of iap-like expression | |
EP1631235A4 (fr) | Compositions et methodes de modulation de l'expression de la proteine b7 | |
AU2003217392A1 (en) | Methods for identifying targeting domains and methods and compositions comprising the same | |
EP1687398A4 (fr) | Constructions d'expressions qui dependent de vih et utilisations associees | |
GB0327050D0 (en) | Therapeutic methods compositions and uses | |
AU2003290763A8 (en) | Modulation of jumonji expression | |
AU2003291263A8 (en) | Methods and compositions for modulating activator protein 1 | |
AU2003295794A8 (en) | Modulation of stat2 expression | |
AU2003266152A1 (en) | COMPOSITIONS FOR INDUCING INCREASED LEVELS OF Beta-CHEMOKINES AND METHODS OF USE THEREFOR |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
PUAK | Availability of information related to the publication of the international search report |
Free format text: ORIGINAL CODE: 0009015 |
|
17P | Request for examination filed |
Effective date: 20051219 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL HR LT LV MK |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07H 21/00 20060101ALI20060320BHEP Ipc: C12N 5/00 20060101ALI20060320BHEP Ipc: A61K 31/70 20060101AFI20060320BHEP |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: BAKER, BRENDA F. Inventor name: FREIER, SUSAN, M. Inventor name: KARRAS, JAMES, G. Inventor name: VICKERS, TIMOTHY, A. Inventor name: BENNETT, FRANK, C. |
|
DAX | Request for extension of the european patent (deleted) | ||
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 11/06 20060101ALI20080407BHEP Ipc: A61K 48/00 20060101ALI20080407BHEP Ipc: C12N 15/11 20060101AFI20080407BHEP |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20080417 |
|
17Q | First examination report despatched |
Effective date: 20100324 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: ISIS PHARMACEUTICALS, INC. |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20121201 |